Advertisement
U.S. markets open in 3 hours 36 minutes

InterCure Ltd. (INCR)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
1.9900+0.1400 (+7.57%)
At close: 04:00PM EDT
2.0200 +0.03 (+1.51%)
Pre-Market: 05:20AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close1.8500
Open1.9500
Bid1.6600 x 3000
Ask2.0000 x 1100
Day's Range1.9200 - 2.0550
52 Week Range0.9900 - 2.8680
Volume83,306
Avg. Volume75,821
Market Cap90.69M
Beta (5Y Monthly)0.20
PE Ratio (TTM)16.58
EPS (TTM)0.1200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.66
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
122% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for INCR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Intercure Ltd.
    PAHC: Lowering target price to $13.00PHIBRO ANIMAL HEALTH CORP-A has an Investment Rating of HOLD; a target price of $13.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    InterCure Provides an Update Regarding Nir Oz Facility

    NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additi

  • GlobeNewswire

    InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

    NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing med

  • GlobeNewswire

    InterCure Wins Cannolam Arbitration Proceeding

    NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (“